[
  {
    "ts": null,
    "headline": "Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?",
    "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
    "url": "https://finnhub.io/api/news?id=88c075135d626958fc2a743ed08887abde2e11f00c032c3ad1b43a6012af3199",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756395007,
      "headline": "Incyte (INCY) Up 9.4% Since Last Earnings Report: Can It Continue?",
      "id": 136561118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
      "url": "https://finnhub.io/api/news?id=88c075135d626958fc2a743ed08887abde2e11f00c032c3ad1b43a6012af3199"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership",
    "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Incyte Corporation stands fourth on our list. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and inflammatory diseases, best known for Jakafi (ruxolitinib), a leading treatment for myelofibrosis and polycythemia vera. Its oncology portfolio also includes MONJUVI for lymphoma, PEMAZYRE for cholangiocarcinoma, ZYNYZ […]",
    "url": "https://finnhub.io/api/news?id=2f46ea7b8d45d2aaa33e7f5e2053cafc09a76b61d409f8b6c3ab6c958a791a93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756371439,
      "headline": "Incyte Corporation (INCY) Expands Precision Medicine with QIAGEN Partnership",
      "id": 136558417,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "We recently published 11 Best Cancer Stocks to Buy Right Now. Incyte Corporation stands fourth on our list. Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on cancer and inflammatory diseases, best known for Jakafi (ruxolitinib), a leading treatment for myelofibrosis and polycythemia vera. Its oncology portfolio also includes MONJUVI for lymphoma, PEMAZYRE for cholangiocarcinoma, ZYNYZ […]",
      "url": "https://finnhub.io/api/news?id=2f46ea7b8d45d2aaa33e7f5e2053cafc09a76b61d409f8b6c3ab6c958a791a93"
    }
  }
]